Takeaways: XORTX’s planned Canadian CTA could strengthen XORLO’s regulatory pathway while generating clinical evidence to support a future U.S. NDA. The proprietary oxypurinol formulation ...
Takeaways: The Enoumena–AOP Health partnership could strengthen Sibboran’s position in Canada’s acute-care cardiovascular market by combining local commercialization with established manuf...
Takeaways: Tevimbra’s completed pCPA negotiations strengthen BeOne’s position in Canada’s NPC immunotherapy market and could establish an early publicly funded first-line option. Prov...
Takeaways: Mint’s expanded partnership with Bayer strengthens its position as a Canadian pharmaceutical distribution partner, broadening its footprint across cardiovascular and women’s health. T...
CELYSTRA’s Dawnzera Approved in Canada for Hereditary Angioedema CELYSTRA Pharma announced that Health Canada has approved Dawnzera (donidalorsen) to prevent hereditary angioedema (HAE) attacks in adu...
Takeaways: Health Canada’s approval of Dawnzera (donidalorsen) gives CELYSTRA a first‑in‑class, RNA‑targeted prophylaxis for hereditary angioedema (HAE) in patients ≥12 years, with Q4W/Q8W...
Takeaways: Completing pCPA negotiations is a key step toward public reimbursement for Nemluvio in Canada, which—once provincial/territorial drug plans list it—should materially expand access for...
Takeaways: The approval of Nduvra (tapinarof) 1% for moderate to severe atopic dermatitis gives Organon a first‑in‑class, steroid‑free topical that can be prescribed by family physicians w...
Pfizer and BioNTech Receive Health Canada Authorization for XFG-Adapted Comirnaty Pfizer and BioNTech received Health Canada authorization for their XFG variant-adapted Comirnaty COVID-19 vaccine for ...
Takeaways: Enrolling the first Canadian patient in ReVeRA‑301 advances Milestone’s plan to seek a single‑study sNDA for etripamil in AFib‑RVR, a substantially larger market than its approved PSV...